Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Sells $90,339.76 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) CEO Alan H. Auerbach sold 25,592 shares of the company's stock in a transaction on Tuesday, July 8th. The stock was sold at an average price of $3.53, for a total transaction of $90,339.76. Following the completion of the transaction, the chief executive officer owned 7,202,481 shares of the company's stock, valued at $25,424,757.93. This trade represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Puma Biotechnology Price Performance

NASDAQ:PBYI traded down $0.13 during midday trading on Friday, hitting $3.39. The company had a trading volume of 300,719 shares, compared to its average volume of 414,077. Puma Biotechnology, Inc. has a 52-week low of $2.23 and a 52-week high of $4.13. The stock's fifty day moving average price is $3.37 and its 200-day moving average price is $3.18. The company has a market capitalization of $168.25 million, a PE ratio of 4.40 and a beta of 1.29. The company has a quick ratio of 1.43, a current ratio of 1.53 and a debt-to-equity ratio of 0.11.

Institutional Trading of Puma Biotechnology

Several institutional investors have recently added to or reduced their stakes in PBYI. Acorn Capital Advisors LLC purchased a new stake in Puma Biotechnology during the fourth quarter valued at about $7,475,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in Puma Biotechnology by 70.6% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 831,689 shares of the biopharmaceutical company's stock valued at $2,462,000 after buying an additional 344,321 shares during the period. Kennedy Capital Management LLC boosted its position in Puma Biotechnology by 36.5% during the fourth quarter. Kennedy Capital Management LLC now owns 809,375 shares of the biopharmaceutical company's stock valued at $2,469,000 after buying an additional 216,329 shares during the period. American Century Companies Inc. boosted its position in Puma Biotechnology by 21.2% during the first quarter. American Century Companies Inc. now owns 1,149,660 shares of the biopharmaceutical company's stock valued at $3,403,000 after buying an additional 201,284 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Puma Biotechnology by 24.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 863,760 shares of the biopharmaceutical company's stock valued at $2,635,000 after buying an additional 170,968 shares during the period. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.